Pediatric idiopathic intracranial hypertension and the underlying endocrine-metabolic dysfunction: A pilot study

Journal of Pediatric Endocrinology and Metabolism

Volumn 27, Issue 1-2, 2014, Pages 107-115

  Salpietro, Vincenzo ^a   Mankad, Kshitij ^b   Kinali, Maria ^d   Adams, Ashok ^b   Valenzise, Mariella ^c   Tortorella, Gaetano ^c   Gitto, Eloisa ^c   Polizzi, Agata ^e,f   Chirico, Valeria ^c   Nicita, Francesco ^g   David, Emanuele ^c   Romeo, Anna Claudia ^c   Squeri, Carlo Attilio ^c   Savasta, Salvatore ^h   Marseglia, Gian Luigi ^h   Arrigo, Teresa ^c   Johanson, Conrad Earl ⁱ   Ruggieri, Martino ^j,k  

^a UNIVERSITY OF MESSINA   (Italy)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MESSINA   (Italy)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e National Centre for Rare Diseases   (Italy)

^f INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ Brown University Program in Neurosurgery   (United States)

^j UNIVERSITY OF CATANIA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

Aldosterone; Childhood obesity; Children; Idiopathic intracranial hypertension; Magnetic resonance imaging; Metabolic syndrome; Pseudotumor cerebri; Spironolactone

Indexed keywords

ACETAZOLAMIDE; GROWTH HORMONE; OCTREOTIDE; RECOMBINANT GROWTH HORMONE; SPIRONOLACTONE;

ADOLESCENT; ARTICLE; CEREBROSPINAL FLUID; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL LABORATORY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYPERALDOSTERONISM; IDIOPATHIC INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; MALE; MEDICAL HISTORY; MEDICAL RECORD; METABOLIC SYNDROME X; MULTIPLE CANCER; NUCLEAR MAGNETIC RESONANCE; OBESITY; PEDIATRIC HOSPITAL; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RETINOL INTOXICATION; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; WEIGHT GAIN; COMPLICATION; ENDOCRINE DISEASE; INTRACRANIAL HYPERTENSION; METABOLIC DISORDER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; INTRACRANIAL HYPERTENSION; MALE; METABOLIC DISEASES; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 84893764241     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2013-0156     Document Type: Article

References (41)

1. Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM. Idiopathic intracranial hypertension (pseudotumour cerebri): descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993;50:78-80.
2. Hacifazlioglu Eldes N, Yilmaz Y. Pseudotumour cerebri in children: etiological, clinical features and treatment modalities. Eur J Paediatr Neurol 2012;16:349-55.
3. Per H, Canpolat M, Gümüş H, Poyrazoǧlu HG, Yikilmaz A, et al. Clinical spectrum of the pseudotumor cerebri in children: etiological, clinical features, treatment and prognosis. Brain Dev 2013;35:561-8.
4. Distelmaier F, Sengler U, Messing-Juenger M, Assmann B, Mayatepek E, et al. Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev 2006;28:190-5.
5. Shapiro I, Shapiro SK. Familial pseudotumor cerebri and the empty sella syndrome. Ann Ophthalmol 1980;12:1045-8.
6. Curry WT Jr, Butler WE, Barker FG II. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery 2005;57:97-108.
7. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991;114:155-80.
8. Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992;37:155-66
9. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema. A case-control study in a headache center. Neurology 1998;51:245-49.
10. Lipton HL, Michelson PE. Pseudotumor cerebri syndrome without papilledema. J Am Med Assoc 1972;220:1591-2.
11. Rush JA. Pseudotumor cerebri: clinical profile and visual outcome in 63 patients. Mayo Clin Proc 1980;55:541-6.
12. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1):9-160.
13. Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol 2007;52:597-617.
14. Phillips PH. Pediatric pseudotumor cerebri. Int Ophthalmol Clin 2012;52:51-9.
15. Traviesa DC, Schwartzman RJ, Glaser JS, Savino P. Familial benign intracranial hypertension. J Neurol Neurosurg Psychiatry 1976;39:420-3.
16. Malm J, Kristensen B, Markgren P, Ekstedt J. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. Neurology 1992;42:851-8.
17. Salpietro V, Polizzi A, Bertè LF, Chimenz R, Chirico V, et al. Idiopathic intracranial hypertension: a unifying neuroendocrine hypothesis through the adrenal-brain axis. Neuro Endocrinol Lett 2012;33:569-73.
18. Weig SG. Asymptomatic idiopathic intracranial hypertension in young children. J Child Neurol 2002;17:239-41.
19. Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012;83:488-94.
20. Salpietro V, Ruggieri M, Sancetta F, Colavita L, D'Angelo G, et al. New insights on the relationship between pseudotumor cerebri and secondary hyperaldosteronism in children. J Hypertens 2012;30:629-30.
21. Weber KT. Aldosteronism revisited: perspectives on less well recognized actions of aldosterone. J Lab Clin Med 2003; 142:71-82.
22. Khan MU, Khalid H, Salpietro V, Weber KT. idiopathic intracranial hypertension associated with either primary or secondary aldosteronism. Am J Med Sci 2012 [Epub ahead of print].
23. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin like growth factor 1, and benign intracranial hypertension. N Engl J Med 1993;329:665-6.
24. Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjo L, et al. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995;61:57-66.
25. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the reninangiotensin system. Metabolism 1990;39:133-7.
26. Panagopoulos GN, Deftereos SN, Tagaris GA, Gryllia M, Kounadi T, et al. Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurol Neurophysiol Neurosci 2007:1.
27. Katz SE, Klisovic DD, O'Dorisio MS, Lynch R, Lubow M. Expression of somatostatin receptors 1 and 2 in human choroid plexus and arachnoid granulations: implications for idiopathic intracranial hypertension. Arch Ophthalmol 2002;120:1540-3.
28. Sugerman H, Windsor A, Bessos M, Wolfe L. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 1997;241:71-9.
29. Whiteley W, Al-Shahi R, Warlow CP, Zeidler M, Lueck CJ. CSF opening pressure: reference interval and the effect of body mass index. Neurology 2006;67:1690-1.
30. Sinclair AJ, Ball AK, Burdon MA, Clarke CE, Stewart PM, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol 2008;201-202:212-20.
31. Lampl Y, Eshel Y, Kessler A, Fux A, Gilad R, et al. Serum leptin level in women with idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2002;72:642-3.
32. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52:401-9.
33. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003;100:14211-6.
34. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117:2253-61.
35. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, et al. Obesity and the metabolic syndrome in children and adolescent N Engl J Med 2004;350:2362-74.
36. Brara SM, Koebnick C, Porter AH, Langer-Gould A. Pediatric idiopathic intracranial hypertension and extreme childhood obesity. J Pediatr 2012;161:602-7.
37. Salpietro V, Chimenz R, Arrigo T, Ruggieri M. Pediatric idiopathic intracranial hypertension and extreme childhood obesity: a role of weight gain. J Pediatr 2013;162:1084.
38. Zada G, Tirosh A, Kaiser UB, Laws ER, Woodmansee WW. Cushing's disease and idiopathic intracranial hypertension: case report and review of underlying pathophysiological mechanisms J Clin Endocrinol Metab 2010;95:4850-4.
39. Sinclair AJ, Onyimba CU, Khosla P, Vijapurapu N, Tomlinson JW, et al. Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus. J Neuroendocrinol 2007;19:614-20.
40. Sowers JR, Whaley-Connell A, Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-83.
41. Kushida A, Tamura H. Retinoic acids induce neurosteroid biosynthesis in human glial GI-1 cells via the induction of steroidogenic genes. J Biochem 2009;146:917-23.